Analyst Ratings For ABIOMED (NASDAQ:ABMD)
Today, Leerink Swann raised its price target on ABIOMED (NASDAQ:ABMD) to per share.
Some recent analyst ratings include
- 2/2/2018-Guggenheim Reiterated Rating of Buy.
- 2/1/2018-Jefferies Group Reiterated Rating of Buy.
- 2/1/2018-Piper Jaffray Companies Reiterated Rating of Overweight .
- 11/1/2017-SunTrust Banks Reiterated Rating of Buy.
- 10/29/2017-BTIG Research Reiterated Rating of Hold.
Recent Insider Trading Activity For ABIOMED (NASDAQ:ABMD)
ABIOMED (NASDAQ:ABMD) has insider ownership of 7.00% and institutional ownership of 90.48%.
- On 10/30/2017 Dorothy E Puhy, Director, sold 6,364 with an average share price of $179.08 per share and the total transaction amounting to $1,139,665.12.
- On 10/30/2017 Michael G Howley, VP, sold 10,000 with an average share price of $178.64 per share and the total transaction amounting to $1,786,400.00.
- On 10/2/2017 Andrew J Greenfield, VP, sold 11,282 with an average share price of $169.32 per share and the total transaction amounting to $1,910,268.24.
- On 8/30/2017 Eric A Md Rose, Director, sold 982 with an average share price of $145.17 per share and the total transaction amounting to $142,556.94.
- On 8/24/2017 Eric A Md Rose, Director, sold 23,018 with an average share price of $151.09 per share and the total transaction amounting to $3,477,789.62.
- On 8/15/2017 Paul Thomas, Director, sold 10,000 with an average share price of $154.71 per share and the total transaction amounting to $1,547,100.00.
- On 7/31/2017 David M Weber, COO, sold 16,500 with an average share price of $147.63 per share and the total transaction amounting to $2,435,895.00.
Recent Trading Activity for ABIOMED (NASDAQ:ABMD)
Shares of ABIOMED closed the previous trading session at with 239804 shares trading hands.